Sagimet Biosciences - Series A (SGMT) closed at $9.08 on November 20, 2026, down 5.6% from the previous close, on volume of 1,396,069 shares (30-day average 1,130,341).
Data as of November 20, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 9, 2026 | Calendar Put Spread | 20-Nov-26 : 15-Jan-27 10 P | 10,000 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 19, 2026. See the largest for 5, 30, 60 and 90 days
Sagimet Biosciences, Inc. Class A (SGMT) Receives a Rating Update from a Top Analyst
TipRanks (Mon, 16-Nov 8:25 AM ET)
Wedbush Remains a Buy on Sagimet Biosciences, Inc. Class A (SGMT)
TipRanks (Mon, 16-Nov 4:45 AM ET)
Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Globe Newswire (Thu, 12-Nov 7:30 AM ET)
Globe Newswire (Thu, 29-Oct 7:00 AM ET)
Globe Newswire (Thu, 22-Oct 7:00 AM ET)
Globe Newswire (Fri, 9-Oct 7:00 AM ET)
Globe Newswire (Thu, 1-Oct 4:31 PM ET)
SGMT Prices $115 Million Offering at $10.00 to Fund Multiple Denifanstat Milestones
Market Chameleon (Wed, 30-Sep 7:38 AM ET)
Sagimet (SGMT) prices $115.0 million equity raise to fund Phase 3 denifanstat acne trial
Market Chameleon (Wed, 30-Sep 3:06 AM ET)
Globe Newswire (Wed, 30-Sep 6:19 AM ET)
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
Sagimet Biosciences - Series A trades on the NASDAQ stock market under the symbol SGMT.
As of November 20, 2026, SGMT stock price declined to $9.08 with 1,396,069 million shares trading.
SGMT has a beta of 2.17, meaning it tends to be more sensitive to market movements. SGMT has a correlation of 0.17 to the broad based SPY ETF.
SGMT has a market cap of $648.02 million. This is considered a Small Cap stock.
In the last 3 years, SGMT traded as high as $20.71 and as low as $1.73.
The top ETF exchange traded funds that SGMT belongs to (by Net Assets): VTI, IWM, XBI, VXF, IBB.
SGMT has outperformed the market in the last year with a price return of +15.7% while the SPY ETF gained +5.2%. However, in the short term, SGMT had mixed performance relative to the market. It has underperformed in the last 3 months, returning -14.2% vs -10.1% return in SPY. But in the last 2 weeks, SGMT shares have fared better than the market returning -0.4% compared to SPY -5.9%.
SGMT support price is $9.13 and resistance is $10.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SGMT shares will trade within this expected range on the day.